Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York
Mandate

Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York

October 17, 2019

Vinge has advised Aprea Therapeutics, Inc. and its subsidiary Aprea Therapeutics AB in connection with its listing on Nasdaq, New York.

The initial public offering price was set to $15 and the biopharmaceutical company sold 6.5 million shares in the IPO to raise $97.75 million. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing cancer therapeutics.

 
Vinge’s team has primarily consisted of Kristina Ekberg, Charlotte Levin, Maria Schultzberg, Anna Thoms and Stina Bengtsson.

Vinge top ranked within intellectual property law

 Vinge’s IP practice group is once again top ranked in IAM’s annual ranking Patent 1000. Håkan Borgenhäll, Malin Malm Waerme and Stojan Arnerstål also receive individual recommendations.
July 06, 2022

New Regulation on foreign subsidies – the Council and the EP has reached an agreement

 On 30 June, the Council and the European Parliament reached a provisional political agreement on a new Foreign Subsidies Regulation, based on a proposal by the Commission of 5 May 2021.
July 05, 2022

New partners and counsel appointed at Vinge’s Malmö and Stockholm offices

Advokat Daniel Daun and advokat Victor Ericsson at Vinge’s Malmö and Stockholm offices respectively have been appointed as new partners as of 1 January 2023. Jacob Jeanrond, Caroline Krassén, Henrik Schön, Maria Dahlin Kolvik, Sara Strandberg and Linn Adelwald have been elected as counsel at Vinge’s Stockholm office.
June 30, 2022